A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Acute Myeloid
Myelodysplastic Syndromes
Classical Hodgkin Lymphoma
Leukemia, B-cell
Leukemia, Hairy Cell
Mastocytosis, Aggressive Systemic
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chronic Myeloid Leukemia

Interventions

DRUG: MGD024

Sponsor

MacroGenics